Shrinks In Sneakers

Tag: Anxiety

  • Post-SSRI Sexual Dysfunction (PSSD): An Emerging Concern

    Post-SSRI Sexual Dysfunction (PSSD): An Emerging Concern

    Antidepressants, particularly selective serotonin reuptake inhibitors (SSRIs), have been a cornerstone of treatment for mood and anxiety disorders for decades. However, as their use has become more widespread, concerns about their side effects—particularly those related to sexual health—have grown. A new wave of attention has focused on Post-SSRI Sexual Dysfunction (PSSD), a phenomenon in which sexual side effects persist even after the discontinuation of SSRI medications.

    What is PSSD?

    It is well-established that up to 50% of patients taking SSRIs experience some degree of sexual dysfunction while on the medication. These effects are usually thought to be transient, resolving within weeks or months after stopping the drug. However, PSSD represents a different and more troubling pattern: persistent sexual dysfunction lasting three months or longer after discontinuing the medication.

    Patients with PSSD frequently report symptoms such as:

    • Genital anesthesia (reduced or absent genital sensation).
    • Anorgasmia (inability to achieve orgasm).
    • Loss of libido (reduced or absent sexual desire).

    In men, erectile dysfunction and ejaculatory issues are common, while women often report reduced arousal and difficulty achieving orgasm. Unlike transient sexual dysfunction, the hallmark of PSSD is its persistence long after the drug has been stopped.

    The Challenge of Evidence

    The evidence supporting PSSD as a formal diagnosis remains limited and primarily consists of:

    • Case reports
    • Case series
    • Observational data, often derived from internet forums and patient advocacy groups

    While these sources highlight distressing patient experiences, they fall at the bottom of the evidence hierarchy. Without randomized controlled trials or large-scale cohort studies, it is impossible to definitively establish causation between SSRI use and PSSD. This lack of robust evidence complicates efforts to understand the true prevalence, biological mechanisms, and risk factors for PSSD.

    Potential Biological Basis

    The exact mechanism of PSSD remains unclear, but hypotheses include:

    1. Serotonin neurotoxicity: Excessive serotonin signaling may lead to long-lasting changes in the central or peripheral nervous systems.
    2. Dopamine suppression: Chronic serotonin elevation may inhibit dopamine pathways, which play a critical role in sexual function.
    3. Receptor desensitization or downregulation: Long-term SSRI use may alter serotonin and other neurotransmitter receptors in ways that persist after discontinuation.

    None of these theories have been definitively proven, and more research is needed to uncover the underlying pathophysiology.

    Prevalence and Diagnosis

    The true prevalence of PSSD is unknown due to the lack of large, high-quality studies. However, anecdotal reports suggest it may be rare but severely impactful for those affected.

    Currently, there are no standardized diagnostic criteria for PSSD. The most common approach involves:

    1. A history of SSRI use.
    2. Persistent sexual dysfunction lasting three months or more after discontinuing the medication.
    3. Symptoms such as genital anesthesia or nipple insensitivity, which are more specific to PSSD compared to general sexual dysfunction.

    What to Do if You Suspect PSSD

    For clinicians and patients encountering persistent sexual dysfunction, it’s essential to first explore modifiable and reversible causes of sexual dysfunction:

    • Lifestyle factors: Obesity, smoking, poor cardiovascular health, and sedentary behavior can contribute to sexual dysfunction.
    • Endocrine issues: Low testosterone or other hormonal imbalances should be evaluated.
    • Medications: Drugs such as finasteride (for hair loss) and isotretinoin (for acne) are also associated with persistent sexual dysfunction and may confound the diagnosis.

    If PSSD remains the primary suspected diagnosis, a timeline of symptoms is crucial. Note when the antidepressant was started, when sexual dysfunction began, and whether the symptoms improved or worsened after stopping the drug.

    The Bottom Line

    PSSD is an evolving area of concern in psychiatry and pharmacology. While current evidence does not definitively prove a causal relationship between SSRIs and persistent sexual dysfunction, the growing number of reports warrants further investigation. Until higher-quality studies emerge, clinicians should approach this condition with empathy and caution.

    Patients experiencing sexual dysfunction should work closely with their healthcare providers to rule out reversible causes and explore management options. For now, the best strategy is awareness, vigilance, and a patient-centered approach to treatment planning.

  • Can β-Blockers Really Delay the Onset and Progression of Huntington’s Disease?

    Can β-Blockers Really Delay the Onset and Progression of Huntington’s Disease?

    Huntington’s disease (HD) is a devastating neurodegenerative disorder that affects individuals and their families on multiple levels. Over the years, I’ve worked with many patients suffering from HD, and it’s difficult to overstate the physical, cognitive, and emotional toll this disease takes. Beyond the progressive motor dysfunctions that eventually rob patients of their independence, the neuropsychiatric symptoms, including severe depression, irritability, and even psychosis, can be equally debilitating. Tragically, suicide risk in this population is alarmingly high, particularly in the early stages when patients are still aware of their prognosis.

    One of the greatest challenges we face in treating Huntington’s disease is the lack of disease-modifying treatments. While therapies exist to help manage symptoms, such as tetrabenazine for chorea or antidepressants for mood disturbances, these interventions only address parts of the disease. To date, there has been little that offers hope for slowing its relentless progression.

    However, a recent article published in JAMA titled “β-Blocker Use and Delayed Onset and Progression of Huntington Disease” has introduced a glimmer of hope. The study explored the potential role of β-blockers in altering the course of HD. These medications, commonly prescribed for hypertension and cardiac conditions, may also have neuroprotective properties. According to the study, β-blocker use was associated with delayed onset and slowed progression of Huntington’s disease. The study analyzed data from a cohort of over 1,000 patients, utilizing longitudinal assessments to measure disease onset and progression. Statistical analysis revealed a significant reduction in the rate of disease progression among patients taking β-blockers compared to those who were not, with a hazard ratio of 0.78 (95% CI, 0.65–0.92; p < 0.01). This is a groundbreaking finding because it suggests a readily available and widely used class of medications could have a profound impact on a previously untreatable condition.

    The way β-blockers work to slow the progression of HD isn’t entirely clear, but it’s thought they might help by reducing brain inflammation and preventing damage caused by overstimulated nerve cells. Furthermore, they could potentially mitigate some of the psychiatric symptoms seen in HD, such as aggression and anxiety, by dampening the overactivity of the sympathetic nervous system.

    For those of us who work closely with this patient population, findings like these provide a much-needed sense of optimism. If future research confirms these results, we may see a shift in how HD is managed. Imagine being able to tell a patient, “We have a medication that might slow this disease’s progression.” That could be life-changing for so many individuals and their families.

    This study is an important reminder that even in diseases where hope seems scarce, progress is being made. For me, it reinforces why we never stop searching for answers—because even small steps forward can eventually change lives in ways we never imagined. It also underscores the importance of continued research and innovation in the field of neurodegenerative disorders. For patients with HD, their loved ones, and the clinicians who care for them, this kind of news is invaluable.

    What are your thoughts on the use of β-blockers for HD? Have you seen this approach applied in your practice or with your patients? Let’s continue the conversation and keep hope alive for those impacted by this challenging disease.

  • Narcissistic Personality Disorder: Two Faces Explained

    Narcissistic Personality Disorder: Two Faces Explained

    The key difference between vulnerable narcissistic personality disorder (NPD) and grandiose NPD lies in how the narcissistic traits are expressed and how the person copes with feelings of inadequacy and low self-esteem. Both fall under the umbrella of narcissistic personality disorder, but they represent different presentations:

    Grandiose Narcissism

    • Core Traits:
      • Overt self-importance and entitlement.
      • A strong sense of superiority and belief in their own greatness.
      • Craving admiration and validation from others.
      • Often charismatic, confident, and socially dominant.
    • Defense Mechanisms:
      • Rely on denial and externalizing blame to avoid feeling vulnerable.
      • Tend to dismiss or belittle others’ opinions if they conflict with their own.
    • Interpersonal Behavior:
      • Exploitative in relationships, using others to bolster their self-esteem.
      • Seek out positions of power or visibility to maintain their inflated self-image.
    • Emotional Regulation:
      • Typically outwardly composed and unbothered, though they may become aggressive or vindictive if their self-image is challenged.

    Vulnerable Narcissism

    • Core Traits:
      • Feelings of inadequacy, hypersensitivity to criticism, and low self-esteem.
      • A covert sense of entitlement—believing they deserve admiration but fearing they won’t get it.
      • A façade of humility or introversion, masking deep insecurities.
    • Defense Mechanisms:
      • Use avoidance and withdrawal to protect themselves from perceived rejection or failure.
      • Internalize blame and self-doubt, leading to cycles of shame and self-criticism.
    • Interpersonal Behavior:
      • Appear shy, reserved, or socially anxious, but they harbor fantasies of being special or recognized.
      • May oscillate between needing reassurance and distancing themselves from others out of fear of being hurt.
    • Emotional Regulation:
      • Prone to depression, anxiety, and mood swings.
      • Vulnerable to feelings of emptiness and envy of others’ success.

    Clinical Distinction

    • While grandiose narcissists may seem outwardly self-assured and dominant, vulnerable narcissists are more likely to present with symptoms resembling mood or anxiety disorders, often masking their narcissistic traits.
    • Both types share a fragile self-esteem at their core but manifest it in opposite ways: grandiose types inflate their self-image, while vulnerable types retreat into themselves.

    Grandiose Narcissism in a Clinical Setting

    Case Example:

    • Presentation: A 45-year-old CEO attends therapy after his spouse threatens divorce, citing his arrogance and lack of empathy. He describes the problem as “Everyone just misunderstands how hard it is to be as driven and successful as me.”
    • Behavior in Session:
      • Dominates conversations, dismisses the therapist’s insights, and subtly challenges their expertise.
      • Boasts about his achievements, financial success, and social status but avoids discussing emotional issues or personal failures.
      • Minimizes his spouse’s complaints as “overreactions,” viewing them as jealous or ungrateful.
    • Underlying Issues:
      • Although he appears self-confident, his grandiosity masks deep fears of failure and inadequacy.
      • His need for admiration and his inability to tolerate criticism create interpersonal conflict.
    • Therapeutic Challenge:
      • Establishing rapport while gently confronting his defensiveness.
      • Helping him acknowledge and address the vulnerability underlying his grandiosity without triggering a withdrawal or rage response.

    Vulnerable Narcissism in a Clinical Setting

    Case Example:

    • Presentation: A 30-year-old graduate student seeks therapy for persistent depression and social anxiety. She describes herself as “a failure” and avoids academic conferences because she feels “everyone there is smarter and more talented.”
    • Behavior in Session:
      • Initially shy and reserved but gradually reveals fantasies of being recognized as brilliant and exceptional in her field.
      • Complains about colleagues receiving awards, feeling envious and deeply resentful, but also guilty for having those feelings.
      • Struggles to accept praise, dismissing it as insincere or undeserved, and reacts strongly to perceived slights or criticism.
    • Underlying Issues:
      • She feels torn between craving recognition and fearing rejection.
      • Her self-esteem depends heavily on external validation, but she avoids situations where she might fail or be criticized.
    • Therapeutic Challenge:
      • Helping her tolerate and process feelings of inadequacy without retreating into shame or avoidance.
      • Building her sense of self-worth independent of external achievements or comparisons.

    Comparison:

    1. Interpersonal Dynamics:
      • Grandiose narcissists demand validation and admiration from others; vulnerable narcissists fear and avoid situations where their insecurities might be exposed.
      • The CEO pressures the therapist to affirm his greatness, while the student fears the therapist will see her as inadequate.
    2. Emotional Reactions:
      • The CEO might react to confrontation with anger or dismissal, while the student might respond with shame or withdrawal.
    3. Defense Mechanisms:
      • Grandiose types externalize blame (“They’re the problem”), whereas vulnerable types internalize it (“I’m the problem”).

    Clinical Insights

    Both types present challenges in therapy:

    • Grandiose narcissists may struggle with self-reflection, requiring careful, non-confrontational approaches to expose vulnerabilities.
    • Vulnerable narcissists are often more willing to explore their insecurities but may require help managing their intense shame and self-doubt.

  • New ASAM and AAAP Guidelines for Stimulant Use Disorder: Key Updates

    New ASAM and AAAP Guidelines for Stimulant Use Disorder: Key Updates

    The American Society of Addiction Medicine (ASAM) and the American Academy of Addiction Psychiatry (AAAP) recently released updated guidelines for the treatment of stimulant use disorder (SUD).

    1. Comprehensive Assessment: The guidelines emphasize a thorough assessment of patients, including the use of validated screening tools to diagnose SUD, assess severity, and identify co-occurring mental health disorders.
    2. Evidence-Based Psychosocial Interventions: Behavioral therapies remain the cornerstone of treatment. Cognitive-behavioral therapy (CBT), contingency management (CM), and motivational interviewing (MI) are recommended due to strong evidence of their efficacy.
    3. Pharmacological Treatments: While no medications are currently FDA-approved specifically for stimulant use disorder, the guidelines discuss off-label use of medications like bupropion and naltrexone, which show promise in reducing stimulant use and cravings in some patients.
    4. Harm Reduction Strategies: Recognizing the importance of harm reduction, the guidelines support interventions like needle exchange programs and education on safer use to reduce the risk of infectious diseases and other health complications.
    5. Integrated Care Models: The guidelines highlight the importance of integrated care that combines medical, psychiatric, and social support services, aiming to provide holistic care tailored to individual patient needs.
    6. Special Populations: Specific recommendations are provided for treating special populations, including pregnant individuals, adolescents, and those with co-occurring mental health disorders, recognizing the unique challenges these groups face.
    7. Recovery Support: Emphasis is placed on long-term recovery support, including peer support groups, vocational training, and housing assistance, to help individuals maintain recovery and improve their quality of life.

    These guidelines represent a significant step forward in the standardization of care for individuals with stimulant use disorder, aiming to improve outcomes through evidence-based, patient-centered approaches. For clinicians, staying informed and implementing these recommendations can greatly enhance the quality of care provided to this population.

  • Breaking Down Barriers: The Impact of Psychotherapy on Suicidal Ideation and Attempts

    Breaking Down Barriers: The Impact of Psychotherapy on Suicidal Ideation and Attempts

    New Insights from JAMA

    This systematic review and meta-analysis dives deep into the impact of both direct and indirect psychotherapy on suicidal ideation and suicide attempts.

    Key takeaways:

    1. Broad Scope: The study analyzed a vast array of data, ensuring a comprehensive overview of psychotherapy’s effectiveness in reducing suicidal thoughts and behaviors.
    2. Direct vs. Indirect Therapy: It highlights the distinct impacts of direct (face-to-face) and indirect (telehealth, self-help) psychotherapeutic approaches.
    3. Hope for Patients: The findings are a beacon of hope, showing significant reductions in suicidal ideation and attempts post-therapy.

    As healthcare providers, this data reinforces the crucial role of psychotherapy in our therapeutic arsenal. It’s a powerful reminder of how our interventions can save lives and offer patients a brighter, more hopeful future.

    For those in psychiatry and mental health care, this is a must-read article that could shape how we approach treatment for individuals at risk.

    Let’s continue to break down barriers and provide life-saving care. 💪✨

    Link to the article: https://jamanetwork.com/journals/jamapsychiatry/article-abstract/2824096

  • 🚨 New Research Alert! 🚨

    🚨 New Research Alert! 🚨

    We’re diving deep into the latest JAMA Psychiatry article on Social Determinants of Health & Suicide-Related Outcomes 🧠💔. This groundbreaking study sheds light on how factors like income, education, and community support play a crucial role in mental health and suicide prevention. 📊🏡💬

    Key Takeaways: 🔍 Social & economic inequalities significantly impact mental well-being. 🛠️ Addressing these factors can save lives and improve outcomes.

    🤝 Community support is more vital than ever.

    💡 With regard to suicide attempt, experience of childhood abuse and maltreatment and sexual assault, gender and sexual minority status, and parental suicide mortality were the strongest risk factors. 

    💡 For suicide mortality, justice system–involved individuals in the community, exposure to others’ and parental suicide, firearm accessibility, divorce, experience in foster care, release from incarceration, and midlife (age 35-65 years) unemployment were the SDOH with consistently strong effects. 

    Join the conversation and let’s work towards a more equitable and supportive world! 🌍✨

    #MentalHealthMatters #JAMAPsychiatry #SocialDeterminants #community #psychiatry #psychiatrist #doctor#mentalhealth #mentalhealthmatters #mentalhealthishealth #SuicidePrevention #HealthEquity #Psychiatry#Research #Wellness 🌈❤️🧠

    🔗 https://jamanetwork.com/journals/jamapsychiatry/article-abstract/2828935

  • The Erosion of Mutual Respect in Mental Health: A Growing Crisis

    The Erosion of Mutual Respect in Mental Health: A Growing Crisis

    An increasing trend I’ve noticed among patients is a lack of respect for mental health professionals who dedicate their lives to helping them. This erosion of mutual respect has become a significant contributor to burnout and emotional exhaustion for those of us working in the field.

    When you choose a career in medicine—especially in mental health—you do so with a desire to help others and make a meaningful difference in their lives. However, what you don’t expect is to face constant verbal abuse, threats, or dismissal of your expertise while you’re doing the best job possible within the constraints of an underfunded and overstretched system.

    Community mental health, in particular, operates under a scarcity of resources—limited staffing, excessive caseloads, inadequate funding, and a never-ending demand for services. These challenges are often compounded by systemic barriers, such as fragmented care, social stigma, and patients’ personal frustrations, which too often are directed at the very people trying to help them.

    It’s important to remember that mental health professionals are human, too. We experience the same range of emotions as anyone else, including pain when our work and intentions are unfairly maligned. The cumulative toll of being met with hostility instead of collaboration can lead to compassion fatigue, a diminished sense of efficacy, and even questioning the value of staying in the profession. This is particularly disheartening in a field where the work is already emotionally taxing by nature.

    We need to address this trend collectively, not just for the sake of providers but also for the patients we serve. Fostering an environment of mutual respect and understanding—on both sides—is crucial. Patients have every right to advocate for their needs and express dissatisfaction when appropriate, but it’s equally essential to recognize the humanity, dedication, and effort of those striving to help them, often in conditions far from ideal.

    For my colleagues who feel disheartened, remember that you’re not alone. Your work matters, and for every challenging interaction, there are also lives you’ve undoubtedly changed for the better—even if it isn’t acknowledged in the moment. And for the system at large, it’s imperative that we address both the external barriers to quality care and the internal culture that makes this kind of disrespect seem increasingly acceptable. If we want mental health care to thrive, we must take care of its providers just as much as its patients.

  • Mindfulness and Meditation for ADHD: A Natural Boost for Focus and Calm

    Mindfulness and Meditation for ADHD: A Natural Boost for Focus and Calm

    ADHD often brings challenges like racing thoughts, impulsivity, and difficulty staying focused. Mindfulness and meditation are powerful tools that can help individuals with ADHD calm their minds, enhance focus, and reduce stress. Backed by research, these practices are accessible and adaptable to everyday life.

    What is Mindfulness?

    Mindfulness is the practice of paying attention to the present moment without judgment. It involves observing your thoughts, feelings, and surroundings with curiosity and acceptance.

    For individuals with ADHD, mindfulness can help manage the constant stream of thoughts and improve attention regulation.

    Benefits of Mindfulness and Meditation for ADHD

    1. Improved Focus: Regular mindfulness practice helps train the brain to redirect attention back to the task at hand.
    2. Reduced Impulsivity: Mindfulness strengthens self-awareness, helping individuals pause before reacting.
    3. Lower Stress Levels: Deep breathing and meditation activate the relaxation response, countering ADHD-related anxiety.
    4. Better Emotional Regulation: Mindfulness helps identify and manage strong emotions before they escalate.

    The Evidence: Mindfulness for ADHD

    Research supports mindfulness and meditation as effective interventions for ADHD:

    • A 2018 meta-analysis found that mindfulness-based interventions significantly improved attention, impulsivity, and emotional regulation in children and adults with ADHD.
    • A 2016 RCT published in Journal of Attention Disorders reported that mindfulness training reduced ADHD symptoms and improved executive functioning in adults.

    How to Start a Mindfulness Practice for ADHD

    1. Breathing Exercises

    • What to Do:
      • Sit comfortably.
      • Focus on your breath as it flows in and out.
      • If your mind wanders, gently bring your focus back to your breath.
    • Duration: Start with 2–5 minutes and gradually increase to 10–15 minutes.
    • Why it Works: Deep breathing calms the nervous system and anchors attention.

    2. Body Scan Meditation

    • What to Do:
      • Lie down or sit comfortably.
      • Close your eyes and focus on each part of your body, starting from your toes and moving upward.
      • Notice sensations, tension, or relaxation.
    • Duration: 5–10 minutes.
    • Why it Works: Increases body awareness and reduces physical restlessness.

    3. Mindful Walking

    • What to Do:
      • Walk slowly and focus on the sensations of your feet touching the ground.
      • Pay attention to the rhythm of your steps and the sounds around you.
    • Duration: 5–10 minutes during breaks or daily walks.
    • Why it Works: Combines movement with mindfulness, making it ADHD-friendly.

    4. Guided Meditations

    • What to Do: Use mindfulness apps like Calm, Headspace, or Insight Timer for ADHD-specific guided sessions.
    • Duration: Sessions range from 5 to 30 minutes.
    • Why it Works: Guided meditations provide structure, making it easier to stay engaged.

    5. One-Minute Check-Ins

    • What to Do:
      • Pause for one minute during the day to notice your breath, thoughts, or surroundings.
      • Ask yourself, “What’s happening right now?”
    • Why it Works: Quick mindfulness breaks ground your attention and reduce overwhelm.

    Tips for Success

    • Start Small: Begin with short sessions and gradually increase as your comfort grows.
    • Be Patient: It’s normal for the ADHD mind to wander. The goal is to notice and gently refocus.
    • Practice Consistently: Aim for 3–5 sessions per week to build the habit.
    • Integrate into Daily Life: Use mindfulness during daily tasks, like eating or brushing your teeth, to stay present.
  • When Expectations Matter: Antidepressant Efficacy vs. Psilocybin’s Unique Impact

    When Expectations Matter: Antidepressant Efficacy vs. Psilocybin’s Unique Impact

    It’s always valuable to challenge our own assumptions, especially in areas as complex as mental health treatment. A secondary analysis of a randomized controlled trial, recently published in JAMA Psychiatry, explored the role of treatment expectancies in the efficacy of psilocybin versus escitalopram for depression.

    I’ve often argued that blinding these studies is challenging, and participants are likely to have higher expectations for psychedelics like psilocybin. However, this analysis provides a nuanced perspective.

    While participants did report higher expectations for psilocybin’s effectiveness compared to escitalopram, expectancy only seemed to impact outcomes in the escitalopram group. A stronger belief in escitalopram’s efficacy correlated with better results for those receiving it. In contrast, expectancy didn’t significantly influence psilocybin’s effectiveness.

    Another intriguing finding: individuals with higher pre-treatment suggestibility showed more significant therapeutic responses to psilocybin—a pattern not observed in the escitalopram group.

    Although this is a secondary analysis and not the final word on the topic, it raises fascinating questions. Could psilocybin’s therapeutic mechanisms be less reliant on patient expectations than traditional antidepressants?

    For now, this remains an open question, but I’ll be closely following future research as it unfolds.

    Link to article: https://pubmed.ncbi.nlm.nih.gov/39653344/

  • L-theanine (LT) supplementation and Mental Health Disorders Does it work?

    L-theanine (LT) supplementation and Mental Health Disorders Does it work?

    L-theanine is a supplement I’ve personally explored, especially during periods of intense study for major exams or when managing a particularly challenging work schedule. I’ve found it to be helpful, especially when paired with caffeine, either by adding it to coffee or using pre-formulated combination products. My general stance on supplements is that they can have a place in treatment, provided they don’t interfere with other therapies. For my patients, I often allow the use of these products as adjuncts when appropriate.

    That said, it’s essential to acknowledge the limitations of supplements like L-theanine. While they may offer some benefit, particularly in mild cases or for specific symptoms, they are unlikely to provide significant relief in severe mental health conditions. Rather than viewing them as standalone alternatives, we should see these natural products as complementary tools—useful additions to comprehensive treatment plans, especially in cases requiring robust intervention.

    A recent systematic review published in BMC Psychiatry examined the effects of L-theanine (LT) supplementation on patients with mental disorders. 

    The review analyzed 11 randomized controlled trials from six countries, focusing on conditions such as schizophrenia, anxiety disorders, and Attention-Deficit/Hyperactivity Disorder (ADHD). The findings suggest that LT supplementation significantly reduces psychiatric symptoms more effectively than control conditions in individuals with these disorders. However, the authors emphasize the need for further studies to validate these findings and explore the underlying mechanisms.

    L-theanine, a non-protein amino acid found in green tea, has been associated with various mental health benefits, including stress reduction and cognitive enhancement. 

    Its potential therapeutic effects in psychiatric disorders are gaining attention, but more research is necessary to fully understand its efficacy and safety.

    In summary, while current evidence indicates that L-theanine supplementation may be beneficial for individuals with certain mental health conditions, further research is essential to confirm these effects and determine appropriate usage guidelines.

    LInk to Article: https://bmcpsychiatry.biomedcentral.com/articles/10.1186/s12888-024-06285-y